Humacyte is trading at $0.53, up 5.61%, alongside a broad market rally. - The S&P 500, Nasdaq and Dow were all higher, with the Nasdaq gaining the most. - Market context attributed the risk-on tone to weak September jobs data and easing expectations for further Fed rate hikes. - No fresh company-specific announcement explaining the October 2 move was found; Humacyte’s latest listed company news was a September 28 conference presentation announcement.